Literature DB >> 21848882

A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

Mark B Geyer1, Judith S Jacobson, Jason Freedman, Diane George, Virginia Moore, Carmella van de Ven, Prakash Satwani, Monica Bhatia, James H Garvin, Mary Brigid Bradley, Lauren Harrison, Erin Morris, Phyllis Della-Latta, Joseph Schwartz, Lee A Baxter-Lowe, Mitchell S Cairo.   

Abstract

Immune reconstitution appears to be delayed following myeloablative conditioning (MAC) and umbilical cord blood transplantation (UCBT) in paediatric recipients. Although reduced toxicity conditioning (RTC) versus MAC prior to allogeneic stem cell transplantation is associated with decreased transplant-related mortality, the effects of RTC versus MAC prior to UCBT on immune reconstitution and risk of graft-versus-host disease (GVHD) are unknown. In 88 consecutive paediatric recipients of UCBT, we assessed immune cell recovery and immunoglobulin reconstitution at days +100, 180 and 365 and analysed risk factors associated with acute and chronic GVHD. Immune cell subset recovery, immunoglobulin reconstitution, and the incidence of opportunistic infections did not differ significantly between MAC versus RTC groups. In a Cox model, MAC versus RTC recipients had significantly higher risk of grade II-IV acute GVHD [Hazard Ratio (HR) 6·1, P = 0·002] as did recipients of 4/6 vs. 5-6/6 HLA-matched UCBT (HR 3·1, P = 0·03), who also had significantly increased risk of chronic GVHD (HR 18·5, P = 0·04). In multivariate analyses, MAC versus RTC was furthermore associated with significantly increased transplant-related (Odds Ratio 26·8, P = 0·008) and overall mortality (HR = 4·1, P = 0·0001). The use of adoptive cellular immunotherapy to accelerate immune reconstitution and prevent and treat opportunistic infections and malignant relapse following UCBT warrants further investigation.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21848882      PMCID: PMC3188698          DOI: 10.1111/j.1365-2141.2011.08822.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  79 in total

Review 1.  Immune reconstitution: from stem cells to lymphocytes.

Authors:  Gay M Crooks; Kenneth Weinberg; Crystal Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

2.  Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.

Authors:  Janet Ayello; Carmella van de Ven; Weiwei Fortino; Cheryl Wade-Harris; Prakash Satwani; Laxmi Baxi; Lynn L Simpson; Warren Sanger; Diana Pickering; Joanne Kurtzberg; Mitchell S Cairo
Journal:  Biol Blood Marrow Transplant       Date:  2006-06       Impact factor: 5.742

3.  Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.

Authors:  Robertson Parkman; Geoff Cohen; Shelly L Carter; Kenneth I Weinberg; Bernadette Masinsin; Eva Guinan; Joanne Kurtzberg; John E Wagner; Nancy A Kernan
Journal:  Biol Blood Marrow Transplant       Date:  2006-09       Impact factor: 5.742

4.  Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity.

Authors:  S Parmar; S N Robinson; K Komanduri; L St John; W Decker; D Xing; H Yang; J McMannis; R Champlin; M de Lima; J Molldrem; A Rieber; M Bonyhadi; R Berenson; E J Shpall
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

5.  Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

Authors:  Navneet S Majhail; Daniel J Weisdorf; John E Wagner; Todd E Defor; Claudio G Brunstein; Linda J Burns
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

6.  Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.

Authors:  Mary Eapen; Pablo Rubinstein; Mei-Jie Zhang; Bruce M Camitta; Cladd Stevens; Mitchell S Cairo; Stella M Davies; John J Doyle; Joanne Kurtzberg; Michael A Pulsipher; Juan J Ortega; Andromachi Scaradavou; Mary M Horowitz; John E Wagner
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

7.  Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.

Authors:  Paul L Martin; Shelly L Carter; Nancy A Kernan; Indira Sahdev; Donna Wall; Daniel Pietryga; John E Wagner; Joanne Kurtzberg
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

8.  Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation.

Authors:  Axel Schulenburg; Michael Fischer; Peter Kalhs; Margit Mitterbauer; Werner Rabitsch; Hildegard T Greinix; Gerda Leitner
Journal:  Leuk Lymphoma       Date:  2005-12

9.  Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs.

Authors:  Stephen B Porter; Baoling Liu; John Rogosheske; Bruce L Levine; Carl H June; Virginia K Kohl; John E Wagner; Jeffrey S Miller; Bruce R Blazar
Journal:  Transplantation       Date:  2006-07-15       Impact factor: 4.939

10.  Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

Authors:  Roberto Rodriguez; Auayporn Nademanee; Nora Ruel; Eileen Smith; Amrita Krishnan; Leslie Popplewell; Jasmine Zain; Kathy Patane; Neil Kogut; Ryotaro Nakamura; Clarence Sarkodee-Adoo; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

View more
  20 in total

Review 1.  Cord Blood Banking for Potential Future Transplantation.

Authors:  William T Shearer; Bertram H Lubin; Mitchell S Cairo; Luigi D Notarangelo
Journal:  Pediatrics       Date:  2017-11       Impact factor: 7.124

2.  A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation.

Authors:  Erin Qualter; Prakash Satwani; Angela Ricci; Zhezhen Jin; Mark B Geyer; Bachir Alobeid; Kavita Radhakrishnan; Michael Bye; William Middlesworth; Phyllis Della-Letta; Gerald Behr; Miguel Muniz; Carmella van de Ven; Lauren Harrison; Erin Morris; Mitchell S Cairo
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-23       Impact factor: 5.742

3.  Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.

Authors:  J Hochberg; L Harrison; E Morris; O Militano; P Brand; S Fabricatore; K Wolownik; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

4.  Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

Authors:  M Bhatia; Z Jin; C Baker; M B Geyer; K Radhakrishnan; E Morris; P Satwani; D George; J Garvin; G Del Toro; W Zuckerman; M T Lee; M Licursi; R Hawks; E Smilow; L A Baxter-Lowe; J Schwartz; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2014-05-05       Impact factor: 5.483

Review 5.  Engineering cord blood to improve engraftment after cord blood transplant.

Authors:  Rohtesh S Mehta; Hema Dave; Catherine M Bollard; Elizabeth J Shpall
Journal:  Stem Cell Investig       Date:  2017-05-25

6.  Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Authors:  P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo
Journal:  Leukemia       Date:  2014-06-18       Impact factor: 11.528

Review 7.  Advances in predicting acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; John E Levine
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

Review 8.  Is genetic rescue of cystinosis an achievable treatment goal?

Authors:  Stephanie Cherqui
Journal:  Nephrol Dial Transplant       Date:  2013-07-16       Impact factor: 5.992

Review 9.  Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.

Authors:  M S Cairo; N Tarek; D A Lee; C Delaney
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

10.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Authors:  E Brissot; F Rialland; X Cahu; M Strullu; N Corradini; C Thomas; N Blin; X Rialland; E Thebaud; P Chevallier; P Moreau; N Milpied; J L Harousseau; F Mechinaud; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.